JP2014520147A - 疾患における組織トランスグルタミナーゼ活性化の調節 - Google Patents

疾患における組織トランスグルタミナーゼ活性化の調節 Download PDF

Info

Publication number
JP2014520147A
JP2014520147A JP2014517091A JP2014517091A JP2014520147A JP 2014520147 A JP2014520147 A JP 2014520147A JP 2014517091 A JP2014517091 A JP 2014517091A JP 2014517091 A JP2014517091 A JP 2014517091A JP 2014520147 A JP2014520147 A JP 2014520147A
Authority
JP
Japan
Prior art keywords
benzo
compound
butyldisulfanyl
imidazole
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014517091A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520147A5 (enExample
Inventor
ディライモンド，トーマス
ジン，シ
クロエック，コーネリアス
コースラ，チャイタン
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ filed Critical ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ
Publication of JP2014520147A publication Critical patent/JP2014520147A/ja
Publication of JP2014520147A5 publication Critical patent/JP2014520147A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
JP2014517091A 2011-06-20 2012-06-19 疾患における組織トランスグルタミナーゼ活性化の調節 Pending JP2014520147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499044P 2011-06-20 2011-06-20
US61/499,044 2011-06-20
PCT/US2012/043150 WO2012177640A2 (en) 2011-06-20 2012-06-19 Modulation of tissue transglutaminase activation in disease

Publications (2)

Publication Number Publication Date
JP2014520147A true JP2014520147A (ja) 2014-08-21
JP2014520147A5 JP2014520147A5 (enExample) 2015-08-13

Family

ID=47423169

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517091A Pending JP2014520147A (ja) 2011-06-20 2012-06-19 疾患における組織トランスグルタミナーゼ活性化の調節

Country Status (6)

Country Link
US (2) US20140322278A1 (enExample)
EP (1) EP2721169A4 (enExample)
JP (1) JP2014520147A (enExample)
AU (1) AU2012273105A1 (enExample)
CA (1) CA2839549A1 (enExample)
WO (1) WO2012177640A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116846A1 (en) * 2014-01-30 2015-08-06 The Board Of Trustees Of The Leland Stanford Junior University Modulation of tissue transglutaminase activation in disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003096979A2 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
JP2007511607A (ja) * 2003-11-18 2007-05-10 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ セリアック病の薬物療法
US20090042806A1 (en) * 2005-08-26 2009-02-12 Chaitan Khosla Transglutaminase inhibitors and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116496A1 (en) * 1996-12-06 2004-06-17 Lynn Kirkpatrick Asymmetric Disulfides and methods of using same
US20040259176A1 (en) * 2003-02-25 2004-12-23 Cerione Richard A. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003096979A2 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
JP2007511607A (ja) * 2003-11-18 2007-05-10 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ セリアック病の薬物療法
US20090042806A1 (en) * 2005-08-26 2009-02-12 Chaitan Khosla Transglutaminase inhibitors and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTONYAK MA, ET AL.: "Phosphoinositide 3-kinase activity is required for retinoic acid-induced expression and activation o", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 17, JPN6016016760, 26 April 2002 (2002-04-26), pages 14712 - 14716, ISSN: 0003314891 *
ELLI L, ET AL.: "Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflamm", LABORATORY INVESTIGATION, vol. 91, no. 3, JPN6016016759, March 2011 (2011-03-01), pages 452 - 461, ISSN: 0003314890 *
TAMAKI H, ET AL.: "Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophag", GASTROENTEROLOGY, vol. 131, no. 4, JPN6016016762, October 2006 (2006-10-01), pages 1110 - 1121, ISSN: 0003314892 *
WILLEMSEN L, ET AL.: "Pivotal Role for JNK MAPK in Regulation of Intestinal Barrier Integrity", GASTROENTEROLOGY, vol. Vol.126, Issue 4, Supplement 2, JPN6016046561, 2004, pages 585, ISSN: 0003454363 *

Also Published As

Publication number Publication date
AU2012273105A1 (en) 2014-01-09
WO2012177640A2 (en) 2012-12-27
CA2839549A1 (en) 2012-12-27
EP2721169A2 (en) 2014-04-23
WO2012177640A3 (en) 2013-03-14
WO2012177640A8 (en) 2014-01-30
EP2721169A4 (en) 2015-06-10
US20170266198A1 (en) 2017-09-21
US20140322278A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
CN104703964B (zh) 取代氨基茚满‑和氨基萘满甲酸及其用途
US7842709B2 (en) Method for treating inflammatory diseases of the digestive tract
AU2008310628B2 (en) Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase
JP2020514352A (ja) 組合せ療法のための医薬組成物
JP2016532668A (ja) 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
EP2059234B1 (en) Method for reducing or alleviating inflammation in the digestive tract
EP3680232B1 (en) Novel anthranilic acid-based compound, and pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
KR20210032439A (ko) 염증성 장 질환을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
AU2018209571A1 (en) Use of cytochrome bc1 complex inhibitor in preparing pharmaceutical composition
WO2019074116A1 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
TW202019877A (zh) 離胺醯氧化酶之鹵化烯丙胺碸衍生物抑制劑及其用途
RU2549441C2 (ru) Способы и фармацевтические композиции для лечения синдрома дауна
SA03240363B1 (ar) استخدام n-(-ميثوكسي-5-ميثيل بيرازين -2-يل)-2-(4- [4،3،1-اوكسا ديازول -2- يل)فينيل) بيريدين- 3- سلفوناميد في علاج السرطان
JP2014520147A (ja) 疾患における組織トランスグルタミナーゼ活性化の調節
AU2017235350A1 (en) Combination therapy for proliferative diseases
EP2210604A1 (en) Pharmaceutical compositions combining a nonsteroidal anti-inflammatory agent and a xanthine oxidase inhibiting agent, which can be used to control and treat gout, gouty arthritis and related diseases
JP2008509899A (ja) 胃腸管の炎症性疾患治療用の細胞特異的コンジュゲートの使用
WO2022048618A1 (en) Methods to treat inflammatory bowel disease
AU2009223644A1 (en) Therapy for disorders of the proximal digestive tract
JPH0959155A (ja) コレステリルエステル転送反応阻害剤
US20250041285A1 (en) Modifying the expression level of a gene encoding an cyclooxygenase enzyme by treating a human subject with a nitroxide
EP4069208A1 (en) Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
CN119745887A (zh) 小分子激动剂tepp-46在制备预防和/或治疗主动脉瘤及相关心血管疾病的药物中的应用
TW201904569A (zh) 膀胱過動的預防劑或治療劑
WO2005102332A1 (ja) 変形性関節症治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170303

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170913